261 related articles for article (PubMed ID: 19325494)
1. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance.
Villers A; Lemaitre L; Haffner J; Puech P
Curr Opin Urol; 2009 May; 19(3):274-82. PubMed ID: 19325494
[TBL] [Abstract][Full Text] [Related]
2. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
Villers A; Puech P; Mouton D; Leroy X; Ballereau C; Lemaitre L
J Urol; 2006 Dec; 176(6 Pt 1):2432-7. PubMed ID: 17085122
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.
Puech P; Potiron E; Lemaitre L; Leroy X; Haber GP; Crouzet S; Kamoi K; Villers A
Urology; 2009 Nov; 74(5):1094-9. PubMed ID: 19773038
[TBL] [Abstract][Full Text] [Related]
6. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature.
Giannarini G; Petralia G; Thoeny HC
Eur Urol; 2012 Feb; 61(2):326-40. PubMed ID: 22000497
[TBL] [Abstract][Full Text] [Related]
7. How good is MRI at detecting and characterising cancer within the prostate?
Kirkham AP; Emberton M; Allen C
Eur Urol; 2006 Dec; 50(6):1163-74; discussion 1175. PubMed ID: 16842903
[TBL] [Abstract][Full Text] [Related]
8. Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography.
Puech P; Huglo D; Petyt G; Lemaitre L; Villers A
Curr Opin Urol; 2009 Mar; 19(2):168-76. PubMed ID: 19188771
[TBL] [Abstract][Full Text] [Related]
9. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
10. [Current role of MRI for the local staging of prostate cancer].
Busquets JC; Batlle JC; Obregón JB; Ortega MV; Morell NR
Arch Esp Urol; 2006 Dec; 59(10):1001-10. PubMed ID: 17283713
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer].
Franiel T; Lüdemann L; Taupitz M; Rost J; Asbach P; Beyersdorff D
Rofo; 2009 Jun; 181(6):536-42. PubMed ID: 19353483
[TBL] [Abstract][Full Text] [Related]
12. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology.
Haffner J; Potiron E; Bouyé S; Puech P; Leroy X; Lemaitre L; Villers A
Prostate; 2009 Feb; 69(3):276-82. PubMed ID: 19016249
[TBL] [Abstract][Full Text] [Related]
13. [Magnetic resonance imaging and prostate cancer].
Cornud F; Villers A; Mongiat-Artus P; Rebillard X; Soulie M;
Prog Urol; 2008 Nov; 18(10):621-33. PubMed ID: 18971104
[TBL] [Abstract][Full Text] [Related]
14. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
15. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology.
Bouyé S; Potiron E; Puech P; Leroy X; Lemaitre L; Villers A
Prostate; 2009 Jan; 69(1):105-13. PubMed ID: 18850578
[TBL] [Abstract][Full Text] [Related]
16. Intraprostatic targeting.
Ukimura O; Faber K; Gill IS
Curr Opin Urol; 2012 Mar; 22(2):97-103. PubMed ID: 22249373
[TBL] [Abstract][Full Text] [Related]
17. Functional magnetic resonance imaging in prostate cancer.
Seitz M; Shukla-Dave A; Bjartell A; Touijer K; Sciarra A; Bastian PJ; Stief C; Hricak H; Graser A
Eur Urol; 2009 Apr; 55(4):801-14. PubMed ID: 19185981
[TBL] [Abstract][Full Text] [Related]
18. Update of prostate magnetic resonance imaging at 3 T.
Kim CK; Park BK
J Comput Assist Tomogr; 2008; 32(2):163-72. PubMed ID: 18379296
[TBL] [Abstract][Full Text] [Related]
19. Endorectal magnetic resonance imaging staging of prostate cancer.
Chandra RV; Heinze S; Dowling R; Shadbolt C; Costello A; Pedersen J
ANZ J Surg; 2007 Oct; 77(10):860-5. PubMed ID: 17803549
[TBL] [Abstract][Full Text] [Related]
20. Multimodality magnetic resonance imaging of prostate cancer.
Engelbrecht MR; Puech P; Colin P; Akin O; Lemaître L; Villers A
J Endourol; 2010 May; 24(5):677-84. PubMed ID: 20443723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
